Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.

Molecular immunology - 1 Jul 2013

Kopp Lisa M, Ray Anish, Denman Cecele J, Senyukov Vladimir S, Somanchi Srinivas S, Zhu Shiguo, Lee Dean A

Abstract excerpt

DNA hypermethylation resulting in aberrant epigenetic silencing plays an important role in the oncogenesis of many cancer types, including acute myelogenous leukemia (AML).(4) The modulation of NK cell receptors and their cognate ligands is a known mechanism of immune escape in AML, and some membrane proteins, such as killer immunoglobulin-like receptors (KIR), are known to be transcriptionally regulated by DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Growth Processes

Share to Cytotoxicity, Immunologic

Share to Decitabine

Share to K562 Cells

Share to Receptors, KIR

Share to Receptors, Natural Killer Cell

Source

Identifiers

PMID: 23328088
DOI: 10.1016/j.molimm.2012.12.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.PMID 23328088Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndromeSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Immunological effects of hypomethylating agents.Semantic proximity Read ↗

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-CellsSemantic proximity Read ↗

Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor TherapySemantic proximity Read ↗

TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDSSemantic proximity Read ↗

DecitabineSemantic proximity Read ↗

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesSemantic proximity Read ↗

Genomic impact of transient low-dose decitabine treatment on primary AML cellsSemantic proximity Read ↗

Dissection of demethylation and toxicity induced gene expression changes after decitabine treatmentSemantic proximity Read ↗

Evolution of decitabine developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.